1. Home
  2. SCYX vs LTBR Comparison

SCYX vs LTBR Comparison

Compare SCYX & LTBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$0.59

Market Cap

26.3M

Sector

Health Care

ML Signal

HOLD

Logo Lightbridge Corporation

LTBR

Lightbridge Corporation

HOLD

Current Price

$13.67

Market Cap

578.2M

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCYX
LTBR
Founded
1999
1992
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Professional Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
26.3M
578.2M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
SCYX
LTBR
Price
$0.59
$13.67
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$3.00
N/A
AVG Volume (30 Days)
371.5K
1.1M
Earning Date
11-05-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,932,000.00
N/A
Revenue This Year
$167.73
N/A
Revenue Next Year
$290.78
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.57
$4.51
52 Week High
$1.49
$31.34

Technical Indicators

Market Signals
Indicator
SCYX
LTBR
Relative Strength Index (RSI) 32.26 38.41
Support Level $0.58 $12.95
Resistance Level $0.63 $15.19
Average True Range (ATR) 0.02 1.07
MACD -0.00 0.04
Stochastic Oscillator 13.20 14.65

Price Performance

Historical Comparison
SCYX
LTBR

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About LTBR Lightbridge Corporation

Lightbridge Corp is a United States-based nuclear fuel technology company. The business activity of the firm is functioned through one business segment, which is the development and commercialization of its nuclear fuel. The Nuclear Fuel Technology segment develops next generation nuclear fuel technology that increases the power output of commercial reactors and reduces the cost of generating electricity. Geographically, its operations are functioned through the region of Unites States.

Share on Social Networks: